98

Bioinformatics of the Brain

[32] M. Pudełek, K. Król, and J. Catapano et al., “Epidermal growth factor

(EGF) augments the invasive potential of human glioblastoma multi-

forme cells via the activation of collaborative EGFR/ROS-dependent

signaling,” International Journal of Molecular Sciences, vol. 21, no. 10,

p. 3605, 2020.

[33] K. E. van der Vos, E. R. Abels, and X. Zhang et al., “Directly vi-

sualized glioblastoma-derived extracellular vesicles transfer RNA to

microglia/macrophages in the brain,” Neuro-Oncology, vol. 18, no. 1,

pp. 58–69, 2015.

[34] X. Zhang, L. Chen, and W.-q. Dang et al., “CCL8 secreted by tumor-

associated macrophages promotes invasion and stemness of glioblastoma

cells via ERK1/2 signaling,” Laboratory Investigation, vol. 100, no. 4,

pp. 619–629, 2020.

[35] F. Hu, M.-C. Ku, and D. Markovic et al., “Glioma-associated mi-

croglial MMP9 expression is upregulated by TLR2 signaling and sen-

sitive to minocycline,” International Journal of Cancer, vol. 135, no. 11,

pp. 2569–2578, 2014.

[36] A. C. C. da Fonseca, H. Wang, and H. Fan et al., “Increased expression of

stress inducible protein 1 in glioma-associated microglia/macrophages,”

Journal of Neuroimmunology, vol. 274, no. 1-2, pp. 71–77, 2014.

[37] T. Hide, Y. Komohara, and Y. Miyasato et al., “Oligodendrocyte pro-

genitor cells and macrophages/microglia produce glioma stem cell niches

at the tumor border,” EBioMedicine, vol. 30, pp. 94–104, 2018.

[38] H. Grégoire, L. Roncali, and A. Rousseau et al., “Targeting tumor as-

sociated macrophages to overcome conventional treatment resistance in

glioblastoma,” Frontiers in Pharmacology, vol. 11, p. 368, 2020.

[39] R. K. Tiwari, S. Singh, and C. L. Gupta et al., “Repolarization

of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand

encapsulating TLR-9 agonist: plausible role in regenerative medicine

against brain tumor,” International Journal of Neuroscience, vol. 131,

no. 6, pp. 591–598, 2021.

[40] K. Kashfi, J. Kannikal, and N. Nath, “Macrophage reprogramming and

cancer therapeutics: role of INOS-derived NO,” Cells, vol. 10, no. 11,

p. 3194, 2021.

[41] I. G. House, P. Savas, and J. Lai, et al., “Macrophage-derived CXCL9

and CXCL10 are required for antitumor immune responses following

immune checkpoint blockade,” Clinical Cancer Research, vol. 26, no. 2,

pp. 487–504, 2020.